We are live on ! Find out more
AYTU icon

AYTU BioPharma

39 hedge funds and large institutions have $12.2M invested in AYTU BioPharma in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

5.18% less ownership

Funds ownership: 20.59% → 15.41% (-5.2%)

22% less funds holding

Funds holding: 50 → 39 (-11)

26% less call options, than puts

Call options by funds: $194K | Put options by funds: $261K

62% less capital inflows, than outflows

Capital inflows: $3.5M | Capital outflows: $9.11M

79% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 14

Holders
39
Holders Change
-11
Holders Change %
-22%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
17
Reduced
10
Closed
14
Calls
$194​K
Puts
$261​K
Net Calls
-⁠$67​K
Net Calls Change
-⁠$633​K

AYTU Hedge Fund Activity: Q3 2021 in Review

39 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2021, worth a combined $12.2M — down 53% from $26M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of AYTU and 3 opened new positions — a net loss of 11 holders — while 10 trimmed existing stakes and 17 added.

The largest buyer was Morgan Stanley, adding an estimated $1.26M. The largest seller was Armistice Capital, exiting entirely with an estimated $6.72M sold.

  • 39 institutional investors held AYTU BioPharma (AYTU) as of Q3 2021, down from 50 in Q2 2021.
  • Funds reported $12.2M of AYTU BioPharma stock for Q3 2021, down 53% quarter-over-quarter.
  • 3 funds opened new AYTU BioPharma positions in Q3 2021 and 14 closed out, a net change of -11 holders.
  • The largest AYTU BioPharma buyer in Q3 2021 was Morgan Stanley, an estimated $1.26M added.
  • The largest AYTU BioPharma seller in Q3 2021 was Armistice Capital, an estimated $6.72M sold.

Based on aggregated 13F filings for Q3 2021.